The NICE guidelines on food allergies and anaphylaxis provide detailed recommendations for the diagnosis, management, and long-term care of individuals, particularly children and young people, at risk of allergies and anaphylaxis. They cover key areas such as taking an allergy-focused clinical history, appropriate diagnostic testing, patient education, and the use of adrenaline auto-injectors. Additionally, the guidelines emphasise the importance of specialist referrals for complex cases and the need for ongoing monitoring to ensure effective management and patient safety.
The NICE quality standard for food allergy (QS118) outlines essential practices for the diagnosis and management of food allergies, particularly in children and young people.
The NICE quality standard for anaphylaxis (QS119) provides essential guidance to improve the care and management of individuals at risk of or experiencing anaphylaxis.
The NICE guideline CG134 outlines crucial recommendations for the recognition, emergency treatment, and ongoing management of anaphylaxis.
The NICE guideline CG183 provides essential guidance for the diagnosis, documentation, and management of drug allergies in adults, children, and young people.
The NICE guideline CG116 addresses the growing concern of food allergies in children and young people. It emphasises the need for early identification through a detailed allergy-focused clinical history and the use of appropriate diagnostic tests. The guideline aims to improve the management of food allergies by providing clear recommendations on diagnosis, treatment, and ongoing care. It also highlights the importance of effective communication with families and carers to ensure they are fully supported throughout the process.
AllergyWise® is an online e-learning course and the easiest way to learn about anaphylaxis, the risks of serious allergies and how to manage them. The courses can be worked through conveniently from your home or workplace, wherever and whenever it suits you. The courses are simple to follow with interactive diagrams and graphics which makes learning about anaphylaxis and teaching those around you easier than ever, no matter who you are or what you do.
Sign up to our free newsletter for healthcare professionals
The National Institute for Health and Care Excellence (NICE) has released its final draft guidance, recommending Acarizax for NHS use in the management of house dust mite allergy. Developed by ALK-Abello, Acarizax is the first therapy specifically designed to treat
[…]
ARS Pharmaceuticals has made significant progress in expanding access to neffy®, its needle-free adrenaline (epinephrine) nasal spray. After gaining approval in the U.S. and Europe for treating severe allergic reactions like anaphylaxis, ARS Pharmaceuticals has now filed for approval in
[…]
A recent announcement from DBV Technologies revealed promising long-term results from its EPITOPE Study. Results from a 3-year study showed that the VIASKIN® Peanut patch can help children with peanut allergies become less sensitive to peanuts, reducing the risk of
[…]